Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 8, 2017 and accepted by EDGAR at Nov 8, 2017, 16:21 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-07-01 to 2017-09-30$7.5mus-gaap:Revenues
Revenue9 months2017-01-01 to 2017-09-30$16.8mus-gaap:Revenues
Cost of revenue3 months2017-07-01 to 2017-09-30$6.1mus-gaap:CostOfRevenue
Cost of revenue9 months2017-01-01 to 2017-09-30$13.7mus-gaap:CostOfRevenue
Gross profit3 months2017-07-01 to 2017-09-30$1.5mus-gaap:GrossProfit
Gross profit9 months2017-01-01 to 2017-09-30$3.1mus-gaap:GrossProfit
Research and development3 months2017-07-01 to 2017-09-30$7.1mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$22.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2017-07-01 to 2017-09-30$2.8mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2017-01-01 to 2017-09-30$8.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2017-07-01 to 2017-09-30−$7.8mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$24.9mus-gaap:OperatingIncomeLoss
Net income3 months2017-07-01 to 2017-09-30−$11.4mus-gaap:NetIncomeLoss
Net income9 months2017-01-01 to 2017-09-30−$70.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.09us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2017-01-01 to 2017-09-30−$0.55us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2017-01-01 to 2017-09-30−$27.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2017-01-01 to 2017-09-30$681.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-09-30$33.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$51.2mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$61.1mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$26.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$87.1mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30−$26.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-057290. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.